Department of Pharmacy Practice and Science
College of Pharmacy
University of Nebraska Medical Center
986145 Nebraska Medical Center
Omaha, NE 68198-6145
Dr. Scarsi practices as an ambulatory clinical pharmacist as part of the University of Nebraska Medical Center HIV Program.
Dr. Scarsi coordinates the Infectious Diseases section of Pharmacotherapy and teaches on topics related to HIV infection and associated opportunistic infections, hormonal contraception, and antimicrobial pharmacokinetics. She also co-coordinates an elective on Advanced Topics in HIV Therapy.
Dr. Scarsi’s research program works to optimize the pharmacologic treatment of persons living with HIV. Her ongoing projects include both domestic and international sites, with an emphasis on women living with HIV and persons co-infected with HIV and tuberculosis. In addition to Dr. Scarsi’s independent research program, she serves as an investigator with the AIDS Clinical Trials Group.
- Podany AT, Bares SH, Havens J, Shetty RD, O'Neill J, Lee S, Fletcher CV, Swindells S, Scarsi KK. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS. 2018 Jan 13. doi: 10.1097/QAD.0000000000001744. [Epub ahead of print]
- Chappell CA, Lamorde M, Nakalema S, Chen BA, Mackline H, Riddler SA, Cohn SE, Darin KM, Achilles SL, Scarsi KK. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. AIDS. 2017 Sep 10; 31(14):1965-72. Epub 2017 Jul 7. doi: 10.1097/QAD.0000000000001591.
- Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, Scarsi KK. The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine. Clin Pharmacol Ther. 2017 Sept; 102(3):529-36. Epub 30 May 2017.
- Scarsi KK, Darin KM, Chappell CA, Nitz SM, Lamorde M. Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV. Drug Saf. 2016 Nov;39(11):1053-72. doi: 10.1007/s40264-016-0452-7. Epub 25 Aug 2016. Review.
- Scarsi KK, Darin KM, Nakalema S, Back DJ, Byakika-Kibwika P, Else LJ, Dilly-Penchala S, Buzibye A, Cohn SE, Merry C, Lamorde M. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clin Infect Dis. 2016 Mar 15;62(6):675-82. doi: 10.1093/cid/civ1001. Epub 2015 Dec 8.
- Scarsi KK, Eisen G, Darin KM, Meloni ST, Rawizza HE, Tchetgen Tchetgen EJ, Agbaji OO, Onwujekwe DI, Gashau W, Nkado R, Okonkwo P, Murphy RL, Kanki PJ. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. Clin Infect Dis. 2016 Feb 15;62(4):512-8. doi: 10.1093/cid/civ928. Epub 2015 Nov 10.
- Podany AT, Scarsi KK, Fletcher CV. Comparative Clinical Pharmacokinetics and pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. Clin Pharmacokinet. 2017 Jan;56(1):25-40. DOI 10.1007/s40262-016-0424-1 Epub 17 June 2016. Review.
- Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK. Artemether-lumefantrine exposure in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. Antimicrob Agents Chemother. 2015 Dec;59(12):7852-6. doi: 10.1128/AAC.01153-15. Epub 2015 Sept 21.
- Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KD, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother. May 2014;69(5):1370-6. Doi: 10.1093/jac/dk513
- Darin KM, Klepser ME, Klepser DG, Klepser SA, Reeves A, Young M, Scarsi KK. Pharmacist-provided rapid HIV testing in two community pharmacies. J Am Pharm Assoc. 2015;55:81-88. doi:10.1331/JAPhA.2015.14070